Lister strain vaccinia virus, a potential therapeutic vector targeting hypoxic tumours

Gene Therapy

Volumn 17, Issue 2, 2010, Pages 281-287

  Hiley, C T ^a   Yuan, M ^a   Lemoine, N R ^a,b   Wang, Y ^a,b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b ZHENGZHOU UNIVERSITY   (China)

Author keywords

Human pancreatic cancer; Hypoxia; Vaccinia virus

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; ONCOLYTIC VIRUS; VIRUS PROTEIN; VIRUS VECTOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; GENE TARGETING; HYPOXIA; NONHUMAN; ONCOLYTIC VIROTHERAPY; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REPORTER GENE; TRANSGENE; VACCINIA VIRUS; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TITRATION;

CELL HYPOXIA; CELL LINE, TUMOR; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; TRANSGENES; VACCINIA VIRUS; VIRAL PROTEINS; VIRUS REPLICATION;

POXVIRIDAE; VACCINIA VIRUS;

EID: 76749114681     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2009.132     Document Type: Article

References (33)

1. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2: 38-47.
2. Hiley CT, Green MML, Shanks JH, Bottomley IC, West CML, Cowan RA et al. Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome. Int J Radiat Oncol Biol Phys 2007; 67: 84-90.
3. Hutchison GJ, Valentine HR, Loncaster JA, Davidson SE, Hunter RD, Roberts SA et al. Hypoxia-inducible factor 1alpha expression as an intrinsic marker of hypoxia: correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix. Clin Cancer Res 2004; 10: 8405-8412.
4. Ghaneh P, Costello E, Neoptolemos JP. Biology and management of pancreatic cancer. Postgrad Med J 2008; 84: 478-497.
5. Koong AC, Mehta VK, Le QT, Fisher GA, Terris DJ, Brown JM et al. Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys 2000; 48: 919-922.
6. Sun HC, Qiu ZJ, Liu J, Sun J, Jiang T, Huang KJ et al. Expression of hypoxia-inducible factor-1 alpha and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis. Int J Oncol 2007; 30: 1359-1367.
7. Yokoi K, Fidler IJ. Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine. Clin Cancer Res 2004; 10: 2299-2306.
8. Hawkins LK, Lemoine NR, Kirn D. Oncolytic biotherapy: a novel therapeutic platform. Lancet Oncol 2002; 3: 17-26.
9. Mulvihill S, Warren R, Venook A, Adler A, Randlev B, Heise C et al. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Therapy 2001; 8: 308-315.
10. Hecht JR, Bedford R, Abbruzzese JL, Lahoti S, Reid TR, Soetikno RM et al. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res 2003; 9: 555-561.
11. Pipiya T, Sauthoff H, Huang YQ, Chang B, Cheng J, Heitner S et al. Hypoxia reduces adenoviral replication in cancer cells by downregulation of viral protein expression. Gene Therapy 2005; 12: 911-917.
12. Shen B, Hermiston T. Effect of hypoxia on Ad5 infection, trans-gene expression and replication. Gene Therapy 2005; 12: 902-910.
13. Shen BH, Bauzon M, Hermiston TW. The effect of hypoxia on the uptake, replication and lytic potential of group B adenovirus type 3 (Ad3) and type 11p (Ad11p). Gene Therapy 2006; 13: 986-990.
14. Fenner F. Smallpox and Its Eradication (History of International Public Health, No. 6). World Health Organization: Geneva, 1988.
15. Smith GL, Moss B. Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA. Gene 1983; 25: 21-28.
16. Schramm B, Locker J. Cytoplasmic organization of POXvirus DNA replication. Traffic 2005; 6: 839-846.
17. Thorne SH. Oncolytic vaccinia virus: from bedside to benchtop and back. Curr Opin Mol Ther 2008; 10: 387-392.
18. Townsley A, Weisberg A, Wagenaar T, Moss B. Vaccinia virus entry into cells via a low-pH-dependent endosomal pathway. J Virol 2006; 80: 8899-8908.
19. Swietach P, Vaughan-Jones RD, Harris AL. Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev 2007; 26: 299-310.
20. Masson N, Ratcliffe PJ. HIF prolyl and asparaginyl hydroxylases in the biological response to intracellular O(2) levels. J Cell Sci 2003; 116: 3041-3049.
21. Kraggerud SM, Sandvik JA, Pettersen EO. Regulation of protein synthesis in human cells exposed to extreme hypoxia. Anticancer Res 1995; 15: 683-686.
22. Hay JG. The potential impact of hypoxia on the success of oncolytic virotherapy. Curr Opin Mol Ther 2005; 7: 353-358.
23. Bhattacharyya M, Lemoine NR. Gene therapy developments for pancreatic cancer. Best Pract Res Clin Gastroenterol 2006; 20: 285-298.
24. Connor JH, Naczki C, Koumenis C, Lyles DS. Replication and cytopathic effect of oncolytic vesicular stomatitis virus in hypoxic tumor cells in vitro and in vivo. J Virol 2004; 78: 8960-8970.
25. Shen B, Bauzon M, Hermiston T. The effect of hypoxia on the uptake, replication and lytic potential of group B adenovirus type 3 (Ad3) and type 11p (Ad11p). Gene Therapy 2006; 13: 986-990.
26. Poland GA, Grabenstein JD, Neff JM. The US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation program. Vaccine 2005; 23: 2078-2081.
27. Roenigk Jr HH, Deodhar S, St Jacques R, Burdick K. Immuno-therapy of malignant melanoma with vaccinia virus. Arch Dermatol 1974; 109: 668-673.
28. Kim JH, Oh JY, Park BH, Lee DE, Kim JS, Park HE et al. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther 2006; 14: 361-370.
29. Park BH, Hwang T, Liu TC, Sze DY, Kim JS, Kwon HC et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 2008; 9: 533-542.
30. Binley K, Iqball S, Kingsman A, Kingsman S, Naylor S. An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer. Gene Therapy 1999; 6: 1721-1727.
31. Binley K, Askham Z, Martin L, Spearman H, Day D, Kingsman S et al. Hypoxia-mediated tumour targeting. Gene Therapy 2003; 10: 540-549.
32. Hung CF, Tsai YC, He L, Coukos G, Fodor I, Qin L et al. Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice. Gene Therapy 2007; 14: 20-29.
33. Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 1938; 27: 493-497.